Yang J, et al. - Researchers analyzed data from randomized controlled trials (RCTs) reporting the use of sublingual immunotherapy (SLIT) for infants, children, and adolescent (aged from 3 to 18 year) with allergic conjunctivitis (AC) or allergic rhinoconjunctivitis (ARC) in order to assess the therapeutic efficacy of SLIT in terms of ameliorating eye symptoms in these patient populations. The studies included in this analysis were identified from Cochrane Library database, EMBASE, and Medline from November 1990 to 2017. This meta-analysis included 13 clinical RCTs. Using SLIT, amelioration of ocular symptoms was achieved in children with ARC or AC. Attenuation of pollen-induced pediatric AC but not mite-induced AC was clearly noted as a result of treatment with SLIT; this was revealed in subgroup analysis.